<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000797.v1.p1" parentStudy="phs000797.v1.p1" createDate="2014-09-03" modDate="2014-10-24">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Gulbu Uzel, MD</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Michael J. Lenardo, MD</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Thomas A. Fleisher, MD</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Stuart G. Tangye, PhD</td><td>Garvan Institute of Medical Research, Sydney, Australia</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Eric Meffre, PhD</td><td>Yale University School of Medicine, New Haven, CT, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>CTLA4 haploinsufficiency and immune dysregulation</StudyNameEntrez>
	<StudyNameReportPage>Immune Dysregulation in Human Subjects with Heterozygous Germline Mutations in <i>CTLA4</i></StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>We identified germline heterozygous mutations in <i>CTLA4</i> in members of four families with severe immune dysregulation. Human <i>CTLA4</i> haploinsufficiency caused dysregulation of FoxP3+ regulatory T (Treg) cells and lymphocytic infiltration of target organs, mimicking <i>Ctla4</i> homozygous mice. Patients also exhibited a B cell phenotype, with progressive loss of B cells and accumulation of autoreactive CD21<sup>lo</sup> B cells. This study demonstrates a critical quantitative role for CTLA-4 in human immune homeostasis.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b>Inclusion criteria</b>: Combination of hypogammaglobulinemia and/or CD4 lymphopenia, and infiltration of at least one non-lymphoid organ [brain, lungs and gastrointestinal tract] with lymphocytic aggregates, autoimmune cytopenia.</p> <p><b>Exclusion criteria</b>: Any known previously identified genetic defects for immune dysregulation and lymphoproliferation</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="25213377"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18845758"/>
		</Publication>
		<Publication>
			<Pubmed pmid="7481803"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20231422"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17060611"/>
		</Publication>
		<Publication>
			<Pubmed pmid="7584144"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Autoimmune enteropathy"/>
		<Disease vocab_source="MESH" vocab_term="Immunodeficiencies, Common Variable"/>
		<Disease vocab_source="MESH" vocab_term="Lung Diseases, Interstitial"/>
		<Disease vocab_source="MESH" vocab_term="Intracranial Central Nervous System Disorders"/>
		<Disease vocab_source="MESH" vocab_term="Anemia, Hemolytic, Autoimmune"/>
		<Disease vocab_source="MESH" vocab_term="Autoimmune Thrombocytopenia"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Gulbu Uzel, MD</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Michael J. Lenardo, MD</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Thomas A. Fleisher, MD</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Stuart G. Tangye, PhD</AttName>
			<Institution>Garvan Institute of Medical Research, Sydney, Australia</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Eric Meffre, PhD</AttName>
			<Institution>Yale University School of Medicine, New Haven, CT, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Dat. Q. Tran, MD</AttName>
			<Institution>University of Texas Medical School, Houston, TX, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Steven M. Holland, MD</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>Intramural Research</AttName>
			<Institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>Intramural Research Program, NIH , CC</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>1066694 (to S.G.T.)</AttName>
			<Institution>National Health and Medical Research Council of Australia (Cancer Council NSW), Canberra, Australia</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>1027400 (to S.G.T.)</AttName>
			<Institution>National Health and Medical Research Council of Australia (Cancer Council NSW), Canberra, Australia</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>1016953 (to S.G.T.)</AttName>
			<Institution>National Health and Medical Research Council of Australia (Cancer Council NSW), Canberra, Australia</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>RG 12-08 (to S.G.T.)</AttName>
			<Institution>National Health and Medical Research Council of Australia (Cancer Council NSW), Canberra, Australia</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>AI071087 (to E.M.)</AttName>
			<Institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>AI095848 (to E.M.)</AttName>
			<Institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>AI061093 (to E.M.)</AttName>
			<Institution>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>5R01HL113304-01 (to D.Q.T.)</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-ADO-IRB-PUB" longName="Disease-Specific (Autoimmune Diseases, IRB, PUB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIAID</DacName>
      <DacFullName>NIAID DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000797.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000797.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000797.v1.p1" FileName="CTLA4_Study_1_DUC.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Autoimmune Diseases, IRB, PUB)</ConsentName>
        <ConsentAbbrev>DS-ADO-IRB-PUB</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Autoimmune Diseases.
Requestor must provide documentation of local IRB approval.
Requestor agrees to make results of studies using the data available to the larger scientific community.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
